Cold-adapted, live attenuated influenza vaccine

Abstract

The recently licensed cold-adapted, live attenuated influenza vaccine (CAIV-T, FluMist™, MedImmune Vaccines Inc.) has the potential to enhance control of epidemic influenza. The intranasal vaccine has proven safety and efficacy. Regulatory constraints and cost of CAIV-T have hampered the introduction of the vaccine in the first year. Unwarranted concern about possible transmission of the virus from vaccine recipients to immunocompromised patients limited use in healthcare personnel. The intense influenza A(H3N2) epidemic of 2003–2004 has underscored the necessity of supplementing current efforts to control influenza. Over 120 deaths have been documented in children – the majority of which have been previously healthy. Use of CAIV-T in children will not only decrease the risk of serious disease, but also dampen the spread of the virus in the community and reduce exposure of patients who are at high risk of complications and death.

• cold-adapted
• epidemic control
• FluMist
• influenza vaccine
• live attenuated influenza vaccine